241 related articles for article (PubMed ID: 29020313)
1. Trends in Invasive Pneumococcal Disease in Cancer Patients After the Introduction of 7-valent Pneumococcal Conjugate Vaccine: A 20-year Longitudinal Study at a Major Urban Cancer Center.
Lee YJ; Huang YT; Kim SJ; Kerpelev M; Gonzalez V; Kaltsas A; Papanicolaou G
Clin Infect Dis; 2018 Jan; 66(2):244-253. PubMed ID: 29020313
[TBL] [Abstract][Full Text] [Related]
2. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway.
Steens A; Bergsaker MA; Aaberge IS; Rønning K; Vestrheim DF
Vaccine; 2013 Dec; 31(52):6232-8. PubMed ID: 24176490
[TBL] [Abstract][Full Text] [Related]
3. Impact of the pneumococcal conjugate vaccines on invasive pneumococcal disease in France, 2001-2012.
Lepoutre A; Varon E; Georges S; Dorléans F; Janoir C; Gutmann L; Lévy-Bruhl D; ;
Vaccine; 2015 Jan; 33(2):359-66. PubMed ID: 25448105
[TBL] [Abstract][Full Text] [Related]
4. Long-term Impact of a "3 + 0" Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, 2002-2014.
Jayasinghe S; Menzies R; Chiu C; Toms C; Blyth CC; Krause V; McIntyre P
Clin Infect Dis; 2017 Jan; 64(2):175-183. PubMed ID: 27986682
[TBL] [Abstract][Full Text] [Related]
5. Incidence of invasive pneumococcal disease before and during an era of use of three different pneumococcal conjugate vaccines in Quebec.
De Wals P; Lefebvre B; Deceuninck G; Longtin J
Vaccine; 2018 Jan; 36(3):421-426. PubMed ID: 29224962
[TBL] [Abstract][Full Text] [Related]
6. The herd effects of infant PCV7/PCV13 sequential implementation on adult invasive pneumococcal disease, six years post implementation; a nationwide study in Israel.
Regev-Yochay G; Katzir M; Strahilevitz J; Rahav G; Finn T; Miron D; Maor Y; Chazan B; Schindler Y; Dagan R;
Vaccine; 2017 Apr; 35(18):2449-2456. PubMed ID: 28342668
[TBL] [Abstract][Full Text] [Related]
7. Recurrent invasive pneumococcal disease in children--host factors and vaccination response.
Ingels HA
Dan Med J; 2015 Jul; 62(7):. PubMed ID: 26183055
[TBL] [Abstract][Full Text] [Related]
8. Forecasting invasive pneumococcal disease trends after the introduction of 13-valent pneumococcal conjugate vaccine in the United States, 2010-2020.
Link-Gelles R; Taylor T; Moore MR;
Vaccine; 2013 May; 31(22):2572-7. PubMed ID: 23583813
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of a 3 + 0 pneumococcal conjugate vaccine schedule against invasive pneumococcal disease among a birth cohort of 1.4 million children in Australia.
Gidding HF; McCallum L; Fathima P; Moore HC; Snelling TL; Blyth CC; Jayasinghe S; Giele C; de Klerk N; Andrews RM; McIntyre PB;
Vaccine; 2018 May; 36(19):2650-2656. PubMed ID: 29627233
[TBL] [Abstract][Full Text] [Related]
10. Invasive pneumococcal disease: Clinical outcomes and patient characteristics 2-6 years after introduction of 7-valent pneumococcal conjugate vaccine compared to the pre-vaccine period, the Netherlands.
Wagenvoort GH; Sanders EA; Vlaminckx BJ; Elberse KE; de Melker HE; van der Ende A; Knol MJ
Vaccine; 2016 Feb; 34(8):1077-85. PubMed ID: 26778420
[TBL] [Abstract][Full Text] [Related]
11. Reduction of invasive pneumococcal disease 3 years after the introduction of the 13-valent conjugate vaccine in the Oxfordshire region of England.
Moore CE; Paul J; Foster D; Mahar SA; Griffiths D; Knox K; Peto TE; Walker AS; Crook DW;
J Infect Dis; 2014 Oct; 210(7):1001-11. PubMed ID: 24719477
[TBL] [Abstract][Full Text] [Related]
12. Effect of pneumococcal conjugate vaccination in Uruguay, a middle-income country.
García Gabarrot G; López Vega M; Pérez Giffoni G; Hernández S; Cardinal P; Félix V; Gabastou JM; Camou T;
PLoS One; 2014; 9(11):e112337. PubMed ID: 25375647
[TBL] [Abstract][Full Text] [Related]
13. Incidence of invasive pneumococcal disease after introduction of the 13-valent conjugate pneumococcal vaccine in British Columbia: A retrospective cohort study.
Vadlamudi NK; Patrick DM; Hoang L; Sadarangani M; Marra F
PLoS One; 2020; 15(9):e0239848. PubMed ID: 32997698
[TBL] [Abstract][Full Text] [Related]
14. Impact of pneumococcal conjugate vaccine (PCV7 and PCV13) on pneumococcal invasive diseases in Italian children and insight into evolution of pneumococcal population structure.
Camilli R; D'Ambrosio F; Del Grosso M; Pimentel de Araujo F; Caporali MG; Del Manso M; Gherardi G; D'Ancona F; Pantosti A;
Vaccine; 2017 Aug; 35(35 Pt B):4587-4593. PubMed ID: 28716556
[TBL] [Abstract][Full Text] [Related]
15. Pneumococcal carriage and invasive disease in children before introduction of the 13-valent conjugate vaccine: comparison with the era before 7-valent conjugate vaccine.
Sharma D; Baughman W; Holst A; Thomas S; Jackson D; da Gloria Carvalho M; Beall B; Satola S; Jerris R; Jain S; Farley MM; Nuorti JP
Pediatr Infect Dis J; 2013 Feb; 32(2):e45-53. PubMed ID: 23080290
[TBL] [Abstract][Full Text] [Related]
16. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance.
Moore MR; Link-Gelles R; Schaffner W; Lynfield R; Lexau C; Bennett NM; Petit S; Zansky SM; Harrison LH; Reingold A; Miller L; Scherzinger K; Thomas A; Farley MM; Zell ER; Taylor TH; Pondo T; Rodgers L; McGee L; Beall B; Jorgensen JH; Whitney CG
Lancet Infect Dis; 2015 Mar; 15(3):301-9. PubMed ID: 25656600
[TBL] [Abstract][Full Text] [Related]
17. Prevention of Antibiotic-Nonsusceptible Invasive Pneumococcal Disease With the 13-Valent Pneumococcal Conjugate Vaccine.
Tomczyk S; Lynfield R; Schaffner W; Reingold A; Miller L; Petit S; Holtzman C; Zansky SM; Thomas A; Baumbach J; Harrison LH; Farley MM; Beall B; McGee L; Gierke R; Pondo T; Kim L
Clin Infect Dis; 2016 May; 62(9):1119-25. PubMed ID: 26908787
[TBL] [Abstract][Full Text] [Related]
18. Nationwide population-based surveillance of invasive pneumococcal disease in Japanese children: Effects of the seven-valent pneumococcal conjugate vaccine.
Suga S; Chang B; Asada K; Akeda H; Nishi J; Okada K; Wakiguchi H; Maeda A; Oda M; Ishiwada N; Saitoh A; Oishi T; Hosoya M; Togashi T; Oishi K; Ihara T
Vaccine; 2015 Nov; 33(45):6054-60. PubMed ID: 26235372
[TBL] [Abstract][Full Text] [Related]
19. Effect of the different 13-valent pneumococcal conjugate vaccination uptakes on the invasive pneumococcal disease in children: Analysis of a hospital-based and population-based surveillance study in Madrid, Spain, 2007-2015.
Picazo J; Ruiz-Contreras J; Casado-Flores J; Negreira S; Baquero F; Hernández-Sampelayo T; Otheo E; Méndez C;
PLoS One; 2017; 12(2):e0172222. PubMed ID: 28207888
[TBL] [Abstract][Full Text] [Related]
20. Impact of 13-valent pneumococcal conjugate vaccination in invasive pneumococcal disease incidence and mortality.
Harboe ZB; Dalby T; Weinberger DM; Benfield T; Mølbak K; Slotved HC; Suppli CH; Konradsen HB; Valentiner-Branth P
Clin Infect Dis; 2014 Oct; 59(8):1066-73. PubMed ID: 25034421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
